News | Breast Imaging | January 15, 2021

Solis Mammography Announces the Acquisition of Progressive Radiology

Progressive Radiology is a leading provider of outpatient medical imaging services in the greater DC metropolitan area

Solis Mammography, the nation’s largest independent provider of breast health and diagnostic services, announced that it has expanded its state-of-the-art multimodality medical imaging capabilities in Maryland, Virginia and Washington, DC through the acquisition of Progressive Radiology.

January 15, 2021 — Solis Mammography, the nation’s largest independent provider of breast health and diagnostic services, announced that it has expanded its state-of-the-art multimodality medical imaging capabilities in Maryland, Virginia and Washington, DC through the acquisition of Progressive Radiology.

Progressive Radiology joins Solis Mammography’s Washington Radiology, another leading medical imaging provider in the DC metropolitan area, in the stable of Solis Mammography’s innovative radiology companies who share a mission of providing the highest quality imaging care with a high-touch patient-centric experience.

“With the addition of Progressive Radiology to the Solis Mammography and Washington Radiology family, we are now able to expand our geographic footprint for outpatient imaging in the DMV region,” said Grant Davies, president and Chief Executive Officer of Solis Mammography. “For more than 45 years, Progressive Radiology has provided advanced diagnostic imaging services to patients and medical providers with their team of board-certified, subspecialized radiologists, many of whom are nationally recognized clinicians and educators. By acquiring Progressive Radiology, we are amplifying our dedication to serving patients with the highest quality of care available.”

“Washington Radiology has built a reputation for being the first to market for technical innovation and clinical leadership, particularly in breast health and women’s imaging, and has a 70-year history of excellence,” he continued. “Progressive Radiology has equally contributed to the changing healthcare landscape with a robust musculoskeletal and sports imaging platform, as well as a specialized focus on neuroradiology and pediatric imaging. Together, we will remain mutually dedicated to delivering an exceptional experience to the women, men and children that we serve, while growing services across the region.”

“I’m looking forward to continuing our tradition of providing an incomparable level of service to our patients and the medical community,” said Adam Starr, CEO of Progressive Radiology. “Our existing radiology team of skilled physicians and technologists will continue to serve our patients and provide the focused expertise the clinical community has come to rely on. And, with Solis’ innovation engine, I’m also looking forward to what the future holds.”

With the acquisition of Progressive Radiology, the combined organization will expand its footprint to 17 imaging center locations with additional growth on the horizon.

For more information: www.solismammo.com

Related Content

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | February 17, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Getty Images

News | Breast Density | February 10, 2021
February 10, 2021 — A mammography screenin...
Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8).

Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8). Image courtesy of Radiology 

News | Breast Imaging | February 10, 2021
February 10, 2021 — Breast cancer death rates have stopped declining for women in the U.S.
After acquiring the molecular breast imaging (MBI) assets from GE Healthcare and Dilon Technologies, Inc., SmartBreast Corporation (SmartBreast), a privately held company focused on breast cancer screening and diagnosis, announced today that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture molecular breast imaging (MBI) systems.
News | Breast Imaging | February 09, 2021
February 9, 2021 — After acquiring the...

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,
Volpara Health, a health technology software company whose integrated breast care platform assists in the delivery of personalized patient care, announced the acquisition of CRA Health, LLC, a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital.

Getty Images

News | Breast Imaging | February 02, 2021
February 2, 2021 — Volpara Health, a health technology software company whose integrated...